Literature DB >> 2170321

Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed beta-lactamase producing strains.

B Giwercman1, P A Lambert, V T Rosdahl, G H Shand, N Høiby.   

Abstract

The development of significant mechanisms of resistance to beta-lactam antibiotics in Pseudomonas aeruginosa in cystic fibrosis (CF) patients have been studied in ten CF patients during a two week course of anti-pseudomonal beta-lactam antibiotic therapy. Sputum samples were collected on days 1, 7 and 15. Entire homogenized sputum samples were examined directly for the number of bacteria resistant to different levels of antibiotics. This allowed the detection of pre-existing resistant subpopulations of bacteria as well as following the changes in beta-lactam antibiotic susceptibility during treatment. P. aeruginosa isolates were characterized by means of sero-grouping, phage- and pyocin-typing. Outer membrane proteins of paired sensitive and resistant strains were characterized. Sonicated extracts of cells were assayed for basal and induced beta-lactamase activity. Beta-lactamase activity was further characterized by isoelectric focusing and inhibition profiles. Our observations were in accordance with the hypothesis that the sensitive inducible population was overrun by the pre-existing resistant subpopulation, during treatment. The resistant in-vivo selected P. aeruginosa population exhibited stable partially derepression but the beta-lactamase inhibitor tazobactam restored beta-lactam antibiotic activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2170321     DOI: 10.1093/jac/26.2.247

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  44 in total

1.  Avidity of anti-P aeruginosa antibodies during chronic infection in patients with cystic fibrosis.

Authors:  O Ciofu; T D Petersen; P Jensen; N Høiby
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

2.  Molecular epidemiological analysis of Pseudomonas aeruginosa strains causing failure of antibiotic therapy in cystic fibrosis patients.

Authors:  E Bingen; E Denamur; B Picard; P Goullet; N Lambert-Zechovsky; P Foucaud; J Navarro; J Elion
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-05       Impact factor: 3.267

Review 3.  Mechanisms of antibiotic resistance in Pseudomonas aeruginosa.

Authors:  P A Lambert
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

4.  Induction of beta-lactamase production in Pseudomonas aeruginosa biofilm.

Authors:  B Giwercman; E T Jensen; N Høiby; A Kharazmi; J W Costerton
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

5.  High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment.

Authors:  B Giwercman; C Meyer; P A Lambert; C Reinert; N Høiby
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 6.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

7.  Pseudomonas aeruginosa isolates from patients with cystic fibrosis have different beta-lactamase expression phenotypes but are homogeneous in the ampC-ampR genetic region.

Authors:  J I Campbell; O Ciofu; N Høiby
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

8.  Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe.

Authors:  Muhammad-Hariri Mustafa; Hussein Chalhoub; Olivier Denis; Ariane Deplano; Anne Vergison; Hector Rodriguez-Villalobos; Michael M Tunney; J Stuart Elborn; Barbara C Kahl; Hamidou Traore; Francis Vanderbist; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

9.  Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  James A Karlowsky; Mellany K Weaver; Clyde Thornsberry; Michael J Dowzicky; Mark E Jones; Daniel F Sahm
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

10.  Genome macrorestriction analysis of diversity and variability of Pseudomonas aeruginosa strains infecting cystic fibrosis patients.

Authors:  M J Struelens; V Schwam; A Deplano; D Baran
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.